Frontiers in Neuroscience (Aug 2018)

The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer’s Disease

  • Lucrezia Cellai,
  • Kevin Carvalho,
  • Emilie Faivre,
  • Aude Deleau,
  • Didier Vieau,
  • Luc Buée,
  • David Blum,
  • Céline Mériaux,
  • Victoria Gomez-Murcia

DOI
https://doi.org/10.3389/fnins.2018.00520
Journal volume & issue
Vol. 12

Abstract

Read online

Alzheimer’s disease (AD) is the most common neurodegenerative disorder in elderly people. AD is characterized by a progressive cognitive decline and it is neuropathologically defined by two hallmarks: extracellular deposits of aggregated β-amyloid (Aβ) peptides and intraneuronal fibrillar aggregates of hyper- and abnormally phosphorylated Tau proteins. AD results from multiple genetic and environmental risk factors. Epidemiological studies reported beneficial effects of caffeine, a non-selective adenosine receptors antagonist. In the present review, we discuss the impact of caffeine and of adenosinergic system modulation on AD, in terms of pathology and therapeutics.

Keywords